Manhattan West Asset Management LLC Makes New Investment in Avantor, Inc. $AVTR

Manhattan West Asset Management LLC acquired a new stake in Avantor, Inc. (NYSE:AVTR – Free Report) during the second quarter, according to its most recent Form 13F filing with the SEC. The institutional investor acquired 224,212 shares of the company’s stock, valued at approximately $2,220,000.

A number of other hedge funds and other institutional investors have also modified their holdings of the company. Royal Bank of Canada lifted its position in shares of Avantor by 104.3% during the 1st quarter. Royal Bank of Canada now owns 203,738 shares of the company’s stock worth $3,302,000 after purchasing an additional 104,022 shares during the last quarter. Empowered Funds LLC increased its holdings in Avantor by 40.3% in the first quarter. Empowered Funds LLC now owns 17,659 shares of the company’s stock valued at $286,000 after buying an additional 5,075 shares during the last quarter. Cetera Investment Advisers raised its stake in Avantor by 40.2% in the second quarter. Cetera Investment Advisers now owns 40,289 shares of the company’s stock valued at $542,000 after buying an additional 11,543 shares in the last quarter. Quantbot Technologies LP acquired a new stake in Avantor in the second quarter valued at $232,000. Finally, Arrowstreet Capital Limited Partnership lifted its holdings in Avantor by 214.9% during the 2nd quarter. Arrowstreet Capital Limited Partnership now owns 124,076 shares of the company’s stock worth $1,670,000 after buying an additional 84,679 shares during the last quarter. 95.08% of the stock is currently owned by institutional investors and hedge funds.

Get Avantor alerts:

Avantor Stock Performance

NYSE AVTR opened at $14.45 on Friday. The company has a fifty day moving average of $11.63 and a two-hundred day moving average of $9.65. The company has a market capitalization of $9.77 billion, a PE ratio of -17.20, a P/E/G ratio of 10.76 and a beta of 0.89. Avantor, Inc. has a 1 year low of $7.26 and a 1 year high of $15.93. The company has a debt-to-equity ratio of 0.65, a current ratio of 1.78 and a quick ratio of 1.18.

Avantor (NYSE:AVTR – Get Free Report) last posted its earnings results on Wednesday, July 29th. The company reported $0.21 EPS for the quarter, topping analysts’ consensus estimates of $0.19 by $0.02. Avantor had a positive return on equity of 9.92% and a negative net margin of 8.81%.The business had revenue of $1.69 billion for the quarter, compared to analysts’ expectations of $1.61 billion. During the same quarter in the previous year, the firm earned $0.24 earnings per share. The business’s revenue was up .5% compared to the same quarter last year. Avantor has set its FY 2026 guidance at 0.800-0.830 EPS. As a group, analysts expect that Avantor, Inc. will post 0.81 earnings per share for the current year.

Analyst Upgrades and Downgrades

Several research firms have recently issued reports on AVTR. Morgan Stanley upped their price objective on Avantor from $10.00 to $14.00 and gave the stock an “equal weight” rating in a research report on Thursday, July 30th. TD Cowen restated a “hold” rating on shares of Avantor in a research note on Wednesday, July 15th. Royal Bank Of Canada upped their price target on Avantor from $9.00 to $14.00 and gave the company a “sector perform” rating in a report on Thursday, July 30th. Evercore set a $10.50 price target on shares of Avantor in a research note on Monday, July 6th. Finally, Wolfe Research raised shares of Avantor from a “strong sell” rating to a “hold” rating in a report on Thursday, July 30th. Two research analysts have rated the stock with a Buy rating, fifteen have assigned a Hold rating and one has given a Sell rating to the company’s stock. Based on data from MarketBeat, Avantor presently has an average rating of “Hold” and an average price target of $12.00.

Check Out Our Latest Analysis on Avantor

About Avantor

(Free Report)

Avantor, Inc (NYSE:AVTR) is a global provider of mission-critical products and services to customers in the biopharma, healthcare, education & government, and advanced technologies & applied materials industries. The company delivers essential solutions that support research, development, production and safety applications. Its product portfolio spans from high-purity chemicals and reagents to biologics and cell culture media, as well as lab equipment, consumables and custom manufacturing services.

Avantor’s offerings are organized across two primary segments.

See Also

• Five stocks we like better than Avantor
• Blueprint for a Boom: SEC Clears the Crypto Runway
• Ross Stores Just Flipped the Off-Price Retail Story After TJX’s Marmaxx Miss
• Advance Auto Parts Plunged, But Its Turnaround Is Still Working
• Is Palo Alto Networks Priced for Perfection Again as AI Security Demand Accelerates?

Want to see what other hedge funds are holding AVTR? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Avantor, Inc. (NYSE:AVTR – Free Report).

Receive News & Ratings for Avantor Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Avantor and related companies with MarketBeat.com's FREE daily email newsletter.